CC
CORT icon

Corton Capital’s Corcept Therapeutics CORT Stock Holding History

Corton Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,672
Closed -$305K – 348
2025
Q1 		$305K Sell
2,672
-3,232
-55% -$197K 1.01% 15
2024
Q4 		$298K Buy
+5,904
New +$309K 0.17% 103
2024
Q3 		– Sell
-11,682
Closed -$380K – 522
2024
Q2 		$380K Sell
11,682
-5,373
-32% -$147K 0.2% 118
2024
Q1 		$430K Buy
17,055
+8,209
+93% +$194K 0.16% 173
2023
Q4 		$287K Buy
+8,846
New +$243K 0.09% 333

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Corton Capital's CORT Position: Q2 2025 in Review

Corton Capital sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 2,672 shares — an estimated $305K sold.

Corton Capital first reported a position in CORT in Q4 2023 and held it in 5 quarters. The position peaked at $430K in Q1 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Corton Capital reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 2,672 Corcept Therapeutics shares in Q2 2025, an estimated $305K.
  • Corton Capital first reported a position in Corcept Therapeutics in Q4 2023 and held it in 5 quarters.
  • Corton Capital's Corcept Therapeutics position peaked at $430K in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.